Valuation : PolyPid Ltd.

Market Cap 104M 89.09M 83.62M 76.37M 144M 9.9B 145M 990M 383M 4.99B 390M 381M 16.54B P/E 2026 *
-5.74x
P/E 2027 * -4.16x
Enterprise Value 104M 89.09M 83.62M 76.37M 144M 9.9B 145M 990M 383M 4.99B 390M 381M 16.54B EV / Sales 2026 *
6.92x
EV / Sales 2027 * 12x
Free-Float
79.96%
Yield 2026 *
-
Yield 2027 * -
1 day+0.20%
1 week+2.00%
Current month+19.11%
1 month+31.03%
3 months+5.58%
6 months+21.09%
Current year+17.74%
1 week 4.96
Extreme 4.96
5.23
1 month 3.71
Extreme 3.713898
5.23
Current year 3.65
Extreme 3.65
5.73
1 year 3.06
Extreme 3.06
5.73
3 years 2.3
Extreme 2.3
9.75
5 years 2.3
Extreme 2.3
289.2
10 years 2.3
Extreme 2.3
583.5
Manager TitleAgeSince
Chief Executive Officer 52 01/07/2022
Director of Finance/CFO 39 -
Chief Tech/Sci/R&D Officer 61 18/08/2025
Director TitleAgeSince
Director/Board Member 84 01/04/2008
Director/Board Member 52 08/08/2022
Director/Board Member 74 01/12/2018
Date Insider Type Main position Quantity % Market Cap.
15/7/26 Free

Director

9,132 0.0896%
15/7/26 Free

Director

9,132 0.0896%
15/7/26 Free

Chairman

9,132 0.0896%
Change 5-day change 1-year change 3-year change Capi.($)
+0.20%+2.00%+49.42%-46.79% 104M
-3.59%-7.10%+61.60%+114.83% 1,060B
-1.15%-1.25%+52.98%+62.41% 651B
-1.09%-1.15%+26.18%+79.22% 465B
-0.41%-1.53%+39.41%+41.27% 365B
-0.66%-0.22%+23.61%+39.35% 300B
-0.13%+1.47%+2.99%+13.17% 258B
-0.43%-0.46%+52.06%+71.75% 238B
-2.11%+0.51%-16.55%-53.96% 210B
-0.46%+0.33%+29.05%+92.67% 184B
Average -0.64%-0.40%+32.08%+41.39% 373.05B
Weighted average by Cap. -0.64%-2.16%+39.79%+67.60%

Financials

2026 *2027 *
Net sales 15M 12.87M 12.08M 11.04M 20.83M 1.43B 20.93M 143M 55.42M 722M 56.32M 55.1M 2.39B 8.68M 7.45M 6.99M 6.38M 12.05M 827M 12.1M 82.71M 32.05M 417M 32.57M 31.87M 1.38B
Net income -20.03M -17.19M -16.13M -14.73M -27.81M -1.91B -27.94M -191M -73.99M -964M -75.19M -73.56M -3.19B -31.55M -27.08M -25.42M -23.21M -43.81M -3.01B -44.02M -301M -117M -1.52B -118M -116M -5.03B
Net Debt - -
Logo PolyPid Ltd.
Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
Employees
72
Date Price Change
26/08/26 USD 5.110 +0.20%
25/08/26 USD 5.100 +2.31%
24/08/26 USD 4.985 -2.25%
21/08/26 USD 5.100 +0.39%
20/08/26 USD 5.080 +1.40%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
5.110USD
Average target price
11.75USD
Spread / Average Target
+129.94%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PYPD Stock